Back to Sectors

OCUL

OCULAR THERAPEUTIX, INC
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BEARISH | 70% | 5/5/2026 | earnings missBEARISH | 60% | 5/5/2026 | margin compressionBULLISH | 90% | 5/5/2026 | guidance raiseNEUTRAL | 50% | 5/5/2026 | regulatory actionBEARISH | 70% | 5/5/2026 | earnings missBEARISH | 60% | 5/5/2026 | margin compressionBULLISH | 90% | 5/5/2026 | guidance raiseNEUTRAL | 50% | 5/5/2026 | regulatory actionBEARISH | 70% | 5/5/2026 | earnings missBEARISH | 60% | 5/5/2026 | margin compressionBULLISH | 90% | 5/5/2026 | guidance raiseNEUTRAL | 50% | 5/5/2026 | regulatory actionBEARISH | 70% | 5/5/2026 | earnings missBEARISH | 60% | 5/5/2026 | margin compressionBULLISH | 90% | 5/5/2026 | guidance raiseNEUTRAL | 50% | 5/5/2026 | regulatory actionBEARISH | 70% | 5/5/2026 | earnings missBEARISH | 60% | 5/5/2026 | margin compressionBULLISH | 90% | 5/5/2026 | guidance raiseNEUTRAL | 50% | 5/5/2026 | regulatory actionBEARISH | 70% | 5/5/2026 | earnings missBEARISH | 60% | 5/5/2026 | margin compressionBULLISH | 90% | 5/5/2026 | guidance raiseNEUTRAL | 50% | 5/5/2026 | regulatory actionBEARISH | 70% | 5/5/2026 | earnings missBEARISH | 60% | 5/5/2026 | margin compressionBULLISH | 90% | 5/5/2026 | guidance raiseNEUTRAL | 50% | 5/5/2026 | regulatory actionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 5

Net loss increased to $88.6 million for the quarter, driven by higher R&D spend.

earnings miss
70%
bearishMay 5

Gross-to-net provisions for DEXTENZA increased to 54.1% of gross sales.

margin compression
60%
bullishMay 5

Pivotal SOL-1 trial met primary and secondary endpoints with high statistical significance.

guidance raise
90%
neutralMay 5

New defamation lawsuit filed by EyePoint, Inc. regarding DURAVYU product candidate.

regulatory action
50%
bearishMay 5

Net loss increased to $88.6 million for the quarter, driven by higher R&D spend.

earnings miss
70%
bearishMay 5

Gross-to-net provisions for DEXTENZA increased to 54.1% of gross sales.

margin compression
60%
bullishMay 5

Pivotal SOL-1 trial met primary and secondary endpoints with high statistical significance.

guidance raise
90%
neutralMay 5

New defamation lawsuit filed by EyePoint, Inc. regarding DURAVYU product candidate.

regulatory action
50%
bearishMay 5

Net loss increased to $88.6 million for the quarter, driven by higher R&D spend.

earnings miss
70%
bearishMay 5

Gross-to-net provisions for DEXTENZA increased to 54.1% of gross sales.

margin compression
60%
bullishMay 5

Pivotal SOL-1 trial met primary and secondary endpoints with high statistical significance.

guidance raise
90%
neutralMay 5

New defamation lawsuit filed by EyePoint, Inc. regarding DURAVYU product candidate.

regulatory action
50%
bearishMay 5

Net loss increased to $88.6 million for the quarter, driven by higher R&D spend.

earnings miss
70%
bearishMay 5

Gross-to-net provisions for DEXTENZA increased to 54.1% of gross sales.

margin compression
60%
bullishMay 5

Pivotal SOL-1 trial met primary and secondary endpoints with high statistical significance.

guidance raise
90%
neutralMay 5

New defamation lawsuit filed by EyePoint, Inc. regarding DURAVYU product candidate.

regulatory action
50%
bearishMay 5

Net loss increased to $88.6 million for the quarter, driven by higher R&D spend.

earnings miss
70%
bearishMay 5

Gross-to-net provisions for DEXTENZA increased to 54.1% of gross sales.

margin compression
60%
bullishMay 5

Pivotal SOL-1 trial met primary and secondary endpoints with high statistical significance.

guidance raise
90%
neutralMay 5

New defamation lawsuit filed by EyePoint, Inc. regarding DURAVYU product candidate.

regulatory action
50%
bearishMay 5

Net loss increased to $88.6 million for the quarter, driven by higher R&D spend.

earnings miss
70%
bearishMay 5

Gross-to-net provisions for DEXTENZA increased to 54.1% of gross sales.

margin compression
60%
bullishMay 5

Pivotal SOL-1 trial met primary and secondary endpoints with high statistical significance.

guidance raise
90%
neutralMay 5

New defamation lawsuit filed by EyePoint, Inc. regarding DURAVYU product candidate.

regulatory action
50%
bearishMay 5

Net loss increased to $88.6 million for the quarter, driven by higher R&D spend.

earnings miss
70%
bearishMay 5

Gross-to-net provisions for DEXTENZA increased to 54.1% of gross sales.

margin compression
60%
bullishMay 5

Pivotal SOL-1 trial met primary and secondary endpoints with high statistical significance.

guidance raise
90%
neutralMay 5

New defamation lawsuit filed by EyePoint, Inc. regarding DURAVYU product candidate.

regulatory action
50%

Filing History

10-QMay 5, 2026

The Q1 2026 filing reveals a company at a pivotal crossroads, balancing breakthrough clinical success against a challenging financial reality. The SOL-1 data provides the necessary validation for AXPAXLI's efficacy, creating a clear path toward an NDA submission. However, the widening gap between the company's current operating losses and its modest product revenue highlights the high-stakes nature of this transition. The market must now weigh the potential for a blockbuster launch against the reality of a high-burn biotech model. Ultimately, the investment thesis hinges on the successful conversion of clinical superiority into commercial adoption. While the cash runway is sufficient for the immediate term, the long-term sustainability of the business depends on AXPAXLI's ability to secure payer acceptance despite a higher adverse event profile. Investors should monitor the upcoming preliminary injunction hearing in the EyePoint litigation and the progress of the HELIOS program as secondary indicators of the company's operational stability.